Vascular Access Complications for Therapeutic Apheresis in Nephrology
NCT ID: NCT05894317
Last Updated: 2025-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2020-06-01
2025-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
USING THE ACCUVEIN DEVICE FOR PATIENTS WHO ARE DIFFICULT TO PERFUSE
NCT06861595
Retrievability and Incidence of Complex Retrieval in Celect Versus Denali Filter
NCT03987321
Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports
NCT00921141
Effect of Taurolidin on Prevention of Bloodstream Infection
NCT00545831
Safety and Initial Performance of the MediSieve Magnetic Haemofiltration System
NCT03786536
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions.
The investigators may enroll all patients receveing therapeutic apheresis for nephrologic indications in North East France.
Nephrologics indications include :
* acute or active antibody mediated rejection (ABMR),
* Goodpasture disease,
* ANCA vasculitis,
* thrombotic microangiopathy (TMA),
* Focal segmental glomerulosclerosis (FSGS),
* HLA or ABO desensitization for kidney transplantation.
Data inclusion period is from June 2020 to June 2022.
The aim of the study is to describe the proportion and type of complication in the population of patient receving therapeutic apheresis for nephrologic disease in the North East France. Te investigators will study the risk factors that are associated with this complications.
The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* centrifugation apheresis treatment
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CORBEL Alice
Dr.CORBEL Alice Nephrology, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luc Frimat, MD PhD
Role: PRINCIPAL_INVESTIGATOR
CHRU NANCY DRCI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Hospital
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022PI162
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.